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The title and discussion associated with Table 1 misrepresented the ongoing trials listed as being based solely on pluripotent stem
cells, when in fact some are based on other cell types. It also omitted one trial being carried out by Osiris Therapeutics. The table
included in the online version of the article and the corresponding text have been amended to correct these misrepresentations.
We apologize for any confusion caused.176 Cell Stem Cell 9, 176, August 5, 2011 ª2011 Elsevier Inc.
